Cancer Research Consortium of West Michigan

NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL

Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts

WF 97116:  A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study

NSABP B55: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Phase III Study. Olaparib vs Placebo. Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy. 

ECOG EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

SWOG S1207: Phase III randomized trial. Endocrine Therapy + Everolimus/Placebo. High-risk hormone receptor positive and HER2/NEU negative breast cancer. Staging I-III.

NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. 

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

CTSU E2112: Phase III Trial;  Endocrine Therapy Plus Entinostat/Placebo; Patients with Hormone Receptor-Positive Advanced Breast Cancer

Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

RTOG 1119: Phase II Randomized Study. WBRT +/- Lapatinib in patients with brain metastasis from HER2-Positive breast cancer. Stage IV.

SCRI BRE 203: A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR).  

ACCRU RU011201I A Randomized Phase III Trial of Eribulin vs Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. Not available at Lakeland HealthCare
Staging: 1st or 2nd Line, Locally Recurrent or Metastatic Stage IV or Stage IIIC Not Amenable To Local Therapy, HER2(-). Treatment: Eribulin vs Paclitaxel

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

CTSU E1Z11: A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Specimen Processing Lab 2/24/14. Stage I - III Adenocarcinoma of the breast. Patients must be ER/PR+. Treatment: Anastrozole. 
 

Alliance A011104: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT) - Newly diagnosed Stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma with a > 2 year life expectancy. Statin/atorvastatin or Placebo